<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Opioid intoxication in children and adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Opioid intoxication in children and adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Opioid intoxication in children and adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shan Yin, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michele M Burns, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 26, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The epidemiology, pharmacology, clinical manifestations, and management of opioid toxicity in children and adolescents are reviewed here.
        </p>
        <p>
         Opioid withdrawal in the pediatric patient and opioid use disorder, intoxication, withdrawal, and treatment in adults are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">
          "Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6505.html" rel="external">
          "Opioid withdrawal in adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several terms are used to describe opioid substances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opioid refers to natural and synthetic substances with morphine-like activity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opiate describes a subclass of opioids consisting of alkaloid compounds extracted from opium, including
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         , heroin,
         <a class="drug drug_pediatric" data-topicid="13178" href="/z/d/drug information/13178.html" rel="external">
          codeine
         </a>
         , and semisynthetic derivatives of the poppy plant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endorphins are endogenous peptides that produce pain relief and comprise another subclass of opioids which includes enkephalins, dynorphins, and beta-endorphins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prescription opioids include
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13178" href="/z/d/drug information/13178.html" rel="external">
          codeine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12918" href="/z/d/drug information/12918.html" rel="external">
          buprenorphine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13364" href="/z/d/drug information/13364.html" rel="external">
          hydromorphone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12580" href="/z/d/drug information/12580.html" rel="external">
          meperidine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12666" href="/z/d/drug information/12666.html" rel="external">
          oxycodone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9733" href="/z/d/drug information/9733.html" rel="external">
          oxymorphone
         </a>
         . Morphine and codeine are derived from opium. Buprenorphine, hydromorphone, oxycodone, and oxymorphone are semisynthetic opioids. Meperidine and methadone are fully synthetic  (
         <a class="graphic graphic_table graphicRef66571" href="/z/d/graphic/66571.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         "Designer" opioids are synthetic derivatives of opioids created in makeshift laboratories and include 3-methylfentanyl (implicated in the Moscow theater hostage crisis of 2002), α-fentanyl ("China White"), desomorphine ("krokodil"), MPTP (1, methyl, 4 phenyl 1,2,3,6 tetrahydropyridine), isotonitazene, brorphine, 2-methyl-AP-237, U-47700, and others [
         <a href="#rid1">
          1-7
         </a>
         ]. The agents in this class of opioids change frequently because of variation in laboratories and the attempt to evade law enforcement. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Pharmacology and cellular toxicology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Opioid adulterants, including krokodil'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These derivatives have a much higher potency than does heroin (up to 1000 times more potent) and have been responsible for deaths caused by inadvertent overdose [
         <a href="#rid1">
          1,2
         </a>
         ]. Other health hazards relating to their use involve impurities from improper synthesis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          Fentanyl
         </a>
         is an opiate with 100 times the potency of
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         . Its analogs can be injected, smoked, or snorted. Street names for fentanyl analogs include "Mexican brown" and "Persian white.” One of the first recognized designer opioids, alpha-methyl-fentanyl, was popularly known as "China White" and appeared in California in 1980 [
         <a href="#rid3">
          3
         </a>
         ]. It is estimated to be a thousand times more potent than heroin. Hundreds of fatal overdoses of "China White" and other fentanyl derivatives occurred as a result of this increased potency [
         <a href="#rid1">
          1
         </a>
         ]. Three-methyl-fentanyl, another fentanyl analog with 16 times the potency of fentanyl, and acetyl fentanyl also have been found in street samples [
         <a href="#rid2">
          2
         </a>
         ]. Carfentanil, a fentanyl derivative typically used as a veterinary anesthetic, has also been found in heroin samples in the United States and Canada [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MPPP (1-methyl-4-phenyl-4-propionoxypiperidine), a
         <a class="drug drug_pediatric" data-topicid="12580" href="/z/d/drug information/12580.html" rel="external">
          meperidine
         </a>
         analog, also known as "new heroin" or "designer heroin," appeared on the streets in the early 1980s. In 1982, one batch of "new heroin" was contaminated through an error in synthesis with a by-product of MPTP (methylphenyltetrahydropyridine) and caused chronic Parkinsonism in many users [
         <a href="#rid4">
          4-6
         </a>
         ]. This incident underscores the dangers of using drugs that are produced in laboratories with no controls for purity or potency.
        </p>
        <p>
        </p>
        <p>
         The definitions for opioid dependence or abuse are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6505.html" rel="external">
          "Opioid withdrawal in adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/306.html" rel="external">
          "Opioid withdrawal in the emergency setting"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Opioid abuse is a major international public health problem with up to 22 million people using opium or heroin worldwide [
         <a href="#rid9">
          9
         </a>
         ]. Recreational use of opioids is high in the adolescent and young adult population:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Centers for Disease Control (CDC) report that deaths from unintentional drug overdoses have been rising steeply in the United States since the early 1990s and are a leading cause of death due to injury [
         <a href="#rid10">
          10,11
         </a>
         ]. Based on CDC data, the pediatric mortality rate from prescription and illicit opioids increased by nearly threefold between 1999 and 2016 [
         <a href="#rid12">
          12
         </a>
         ]. In 2021,
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         was implicated in 94 percent of deaths, compared with only 5 percent in 1999; between 2013 and 2021, the mortality rate from fentanyl increased 37-fold [
         <a href="#rid13">
          13
         </a>
         ]. Death is thought to be secondary to respiratory depression, although prolongation of the QT interval in patients on
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         may also be contributory. While mortality is highest in people ages 45 to 54 years of age, adolescents and young adults are seen in emergency departments more frequently from abuse of opioids and other drugs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         From 1997 to 2012, hospitalizations for prescription opioid poisoning among United States children 1 to 19 years of age increased to an annual incidence of 3.7 admissions per 100,000 children [
         <a href="#rid14">
          14
         </a>
         ]. Marked increases in admissions caused by heroin and
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         poisoning were also seen during this time frame among adolescents 15 to 19 years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonmedical use of prescription opioids was reported by 9 percent of a nationally representative sample of high school seniors in the United States during 2007 to 2009 [
         <a href="#rid15">
          15
         </a>
         ]. Intranasal use of prescription opioids was described by 37 percent of nonmedical prescription opioid users. In 2010, 68 percent of all opioid overdoses involved prescription medications with 5000 children younger than 17 years of age requiring emergency department treatment [
         <a href="#rid16">
          16
         </a>
         ]. From 2000 to 2015, the rate of prescription opioid poisoning among teenagers, based upon almost 190,000 poison control center calls, varied from 20 to 40 exposures per 100,000 children with exposures due to suspected suicide increasing over 50 percent during the study period [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Annual health care costs in the United States due to prescription opioid abuse are estimated to be greater than 25 billion dollars [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In children under age six years, opioid intoxication typically occurs as an exploratory ingestion of prescription opioids that were available within their environment. Some of these medications, such as
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12918" href="/z/d/drug information/12918.html" rel="external">
          buprenorphine
         </a>
         pills or
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         patches, may cause life-threatening respiratory depression or death despite ingestion of only one or two pills or exposure to one patch [
         <a href="#rid17">
          17,19-29
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the United States,
         <a class="drug drug_pediatric" data-topicid="12918" href="/z/d/drug information/12918.html" rel="external">
          buprenorphine
         </a>
         was the oral prescription opioid accounting for the most emergency hospitalizations for poisoning in children younger than six years of age from 2007 to 2011 [
         <a href="#rid30">
          30
         </a>
         ]. Buprenorphine ingestion by children younger than six years of age is associated with high rates of hospital admissions (up to 45 percent) and serious medical outcomes (over 20 percent of exposures) [
         <a href="#rid31">
          31
         </a>
         ]. If available, unit dose packaging of buprenorphine may decrease hospitalization [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among children younger than six years of age,
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         prescribed to caregivers and accessible to the child in their home was the most common opioid involved in deaths based on 2010 to 2018 data from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System Poison Center Program [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         From 2005 to 2018, opioids increasingly contributed to fatal poisonings in children ≤5 years of age [
         <a href="#rid34">
          34
         </a>
         ]. Opioids contributed to 24 percent of deaths in 2005 compared with 52 percent in 2018 and were the most common substance contributing to death during the study period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children can also be exposed to opioids maliciously by their caretakers or inadvertently in households where illegal drugs are accessible, often with fatal results [
         <a href="#rid35">
          35-37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6600.html" rel="external">
          "Physical child abuse: Diagnostic evaluation and management", section on 'Toxicology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          PHARMACOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The activity of opioids resembles that of the body's endogenous opioid peptides (enkephalins, endorphins, and dynorphins) [
         <a href="#rid38">
          38
         </a>
         ]. Opioid peptides produce their effects through interaction with receptors throughout the nervous system and the gastrointestinal tract. In contrast, local anesthetics alter pain sensory thresholds.
        </p>
        <p class="headingAnchor" id="H20287450">
         <span class="h2">
          Mechanism of action and pharmacokinetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three types of receptors have been identified: mu (µ), kappa (k), and delta (δ); most opioids interact with more than one type [
         <a href="#rid38">
          38
         </a>
         ]. An opioid-receptor-like 1 (ORL-1) receptor or "orphan" receptor has also been described [
         <a href="#rid38">
          38
         </a>
         ]. The primary sites of opioid action are the limbic system, thalamus, and hypothalamus.
        </p>
        <p>
         In 1996, there was a proposal by the International Union of Basic and Clinical Pharmacology (IUPHAR) to rename the opioid receptors OP3, OP2, OP1, and OP4 respectively although this nomenclature has not been widely adopted [
         <a href="#rid39">
          39
         </a>
         ]. The IUPHAR has subsequently recommended adopting the terms MOP, KOP, DOP, and NOP [
         <a href="#rid40">
          40
         </a>
         ]. However, the original Greek letter nomenclature still predominates.
        </p>
        <p>
         Opioids are classified into three groups based upon their actions [
         <a href="#rid38">
          38
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Morphine-like opioid agonists, which include heroin,
         <a class="drug drug_pediatric" data-topicid="13178" href="/z/d/drug information/13178.html" rel="external">
          codeine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12580" href="/z/d/drug information/12580.html" rel="external">
          meperidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">
          hydrocodone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13237" href="/z/d/drug information/13237.html" rel="external">
          diphenoxylate-atropine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12561" href="/z/d/drug information/12561.html" rel="external">
          loperamide
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opioid antagonists, which competitively block receptor activation by occupying opioid receptor sites. Examples include
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="135038" href="/z/d/drug information/135038.html" rel="external">
          nalmefene
         </a>
         , and
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          naltrexone
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mixed agonist-antagonists/partial agonists, which have different effects depending upon the predominance of agonistic or antagonistic activity in the opioid receptor and prior exposure to opioids.
        </p>
        <p>
        </p>
        <p>
         The use of a mixed agent in an opioid-naive subject results in analgesia and possibly dependence if the agent is used for a long period of time. On the other hand, the use of a mixed agent in an opioid dependent subject may result in withdrawal. Examples of drugs in this class include
         <a class="drug drug_pediatric" data-topicid="12692" href="/z/d/drug information/12692.html" rel="external">
          pentazocine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12627" href="/z/d/drug information/12627.html" rel="external">
          nalbuphine
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12918" href="/z/d/drug information/12918.html" rel="external">
          buprenorphine
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacokinetics
         </strong>
         – The pharmacokinetics of opioids in children between age 1 and 15 years are similar to those in adults [
         <a href="#rid41">
          41
         </a>
         ]. Intravenous use of opioids gives an immediate euphoric effect, subcutaneous administration produces euphoria in 15 minutes, and snorting leads to effect in approximately 30 minutes. When taken orally, opioids such as
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         typically produce a peak effect in four to six hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical effects of pharmacological doses of most opioids persist for three to six hours;
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         for one hour; and
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         for 24 to 48 hours [
         <a href="#rid38">
          38
         </a>
         ]. The absorption of orally administered
         <a class="drug drug_pediatric" data-topicid="13237" href="/z/d/drug information/13237.html" rel="external">
          diphenoxylate-atropine
         </a>
         (Lomotil) usually is delayed because of the
         <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">
          atropine
         </a>
         (anticholinergic) component.
         <a class="drug drug_pediatric" data-topicid="12580" href="/z/d/drug information/12580.html" rel="external">
          Meperidine
         </a>
         has erratic absorption when it is used intramuscularly [
         <a href="#rid42">
          42
         </a>
         ]. The toxicokinetics of opioid drugs after overdose have not been fully defined leading to uncertainty as to the length of time necessary for observation of the asymptomatic patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metabolism
         </strong>
         – Most opioids are metabolized by the liver. Patients with liver disease have impaired metabolism and are at increased risk for toxicity caused by accumulation of active metabolites [
         <a href="#rid41">
          41
         </a>
         ]. The active metabolites of opioids bind to specific mu, delta, and kappa receptors in the central nervous system (CNS) to elicit their clinical effects. The µ2 receptor mediates many of the life-threatening effects, including respiratory depression. CYP 2D6 is the enzyme responsible for converting
         <a class="drug drug_pediatric" data-topicid="13178" href="/z/d/drug information/13178.html" rel="external">
          codeine
         </a>
         to
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         , for example, and individuals with duplicate genes are considered to be ultrarapid metabolizers with an increased risk for toxicity [
         <a href="#rid43">
          43
         </a>
         ]. Opioid metabolites are excreted primarily by the kidneys and can be detected on urine drug screen up to four days after the last use (occasionally longer in chronic users) [
         <a href="#rid41">
          41
         </a>
         ]. Renal dysfunction can lead to toxicity caused by accumulation of active metabolites.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug interactions
         </strong>
         – Opioids interact with various drugs [
         <a href="#rid41">
          41,44
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Proserotonergic opioids such as
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12580" href="/z/d/drug information/12580.html" rel="external">
          meperidine
         </a>
         in combination with monoamine oxidase inhibitors, serotonin-specific reuptake inhibitors, and cyclic antidepressants can produce serotonin syndrome [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Phenothiazines potentiate the action of opioids, possibly by interfering with their metabolism.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cyclic antidepressants increase the bioavailability and plasma level of opioids.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Several drugs impact metabolism of opioids through inhibition or induction of cytochrome oxidase enzyme systems. For example,
         <a class="drug drug_pediatric" data-topicid="13156" href="/z/d/drug information/13156.html" rel="external">
          cimetidine
         </a>
         may enhance effects through prolonging the duration of action. Certain antibiotics may increase (
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          erythromycin
         </a>
         ) or decrease (
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         ) opioid effects.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H886416">
         <span class="h2">
          Morphine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Compared with intravenous administration, sublingual, buccal, and sustained-release preparations of
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         have delayed absorption, attenuating and delaying the peak plasma concentrations. Sustained-release morphine attains one-half the peak plasma level of a comparable dose of immediate-release morphine; levels peak three to four hours after use and depending upon preparation provide pain relief in opioid naïve patients from 4 to 10 hours [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          Morphine
         </a>
         's main metabolite, morphine-6-glucuronide, is more potent than morphine and is responsible for most of the clinical effects [
         <a href="#rid41">
          41
         </a>
         ]. It can be detected in large quantities soon after oral or intravenous administration and levels directly correlate with medication effect as described above. (See
         <a class="local">
          'Mechanism of action and pharmacokinetics'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H886423">
         <span class="h2">
          Heroin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Heroin (diacetylmorphine) is the prototypic recreationally abused opioid, and it is sold under various creative street names Heroin is produced as a pure white crystal or impure tar-like substance, depending upon the supplier. It is typically adulterated with lactose, procaine, calcium-channel blockers,
         <a class="drug drug_pediatric" data-topicid="12570" href="/z/d/drug information/12570.html" rel="external">
          mannitol
         </a>
         , dextrose, talc, or other substances [
         <a href="#rid46">
          46
         </a>
         ]; final concentration varies between 1 to 20 mg per dose from dealer to dealer and day to day. For this reason, overdoses are more likely to occur with heroin than with prescription opiates.
        </p>
        <p>
         Heroin typically is injected. It has a quick onset and brief duration of action. It is rapidly cleared by the liver and excreted in the urine as
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         . The pharmacokinetics of inhaling heroin fumes ("chasing the dragon") or smoking cigarettes dipped in heroin ("ack ack") are similar to that of heroin that is injected intravenously. Chronic fume inhalation can result in spongiform leukoencephalopathy and may represent chronic aluminum toxicity [
         <a href="#rid47">
          47
         </a>
         ]. In one study, the blood concentrations of heroin, either inhaled or intravenous peaked within one to five minutes and decreased to the limit of detection within 30 minutes [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Routes of use
         </span>
         <span class="headingEndMark">
          —
         </span>
         Opioids can be administered intravenously ("mainlining"), subcutaneously ("skin popping"), intranasally ("snorting"), orally, or by inhaling (smoking, "free-basing," "chasing the dragon"). Most American adolescents initiate heroin or prescription opioid use by snorting because snorting requires minimal equipment, is not associated with the health risks of injection, and the onset of action is rapid enough to produce euphoria (the "rush") [
         <a href="#rid15">
          15,49
         </a>
         ]. Cases of "body packing" (swallowing large amounts of well-packaged opioids for the purpose of smuggling) have also been described in children and adolescents [
         <a href="#rid50">
          50,51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/327.html" rel="external">
          "Internal concealment of drugs of abuse (body packing)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of opioid overdose is based upon the history and physical examination.
        </p>
        <p class="headingAnchor" id="H886646">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinician should attempt to identify the specific drug, dose, and formulation to which the patient was exposed, the presence of nonopioid co-exposures, and the individual's prior history of opioid use. In young children, the history is typically a small, exploratory ingestion and a list of drugs available within the child’s environment should be detailed. The caregiver should also be asked about administration of medicines containing
         <a class="drug drug_pediatric" data-topicid="13237" href="/z/d/drug information/13237.html" rel="external">
          diphenoxylate-atropine
         </a>
         (eg, Lomotil) or
         <a class="drug drug_pediatric" data-topicid="13220" href="/z/d/drug information/13220.html" rel="external">
          dextromethorphan
         </a>
         (present in many over-the-counter cough medicines), both of which can cause serious opioid toxicity in young children [
         <a href="#rid52">
          52,53
         </a>
         ]. When infants or young children are ultimately identified with serious opioid overdose and there is no clear initial history of opioid use, health care providers should give consideration to the possibility of a malicious intentional overdose by a caregiver.
        </p>
        <p>
         In adolescents, opioid exposures will fall into one of several categories: recreational use, intended self-harm, or attempt to hide drugs from law enforcement out of fear for arrest ("body stuffing"), or rarely, swallowing large quantities of packaged drugs in order to transport them across borders ("body packing"). In this patient population, additional history should identify the likelihood of trauma (particularly head trauma) and sexual assault. Often, emergency medical services reports regarding where and how the patient was found and whether they were partially or fully undressed can assist in identifying physical or sexual assault.
        </p>
        <p class="headingAnchor" id="H886653">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The classic findings of opioid toxicity are  (
         <a class="graphic graphic_table graphicRef56801" href="/z/d/graphic/56801.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef69375" href="/z/d/graphic/69375.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Miosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Central nervous system (CNS) depression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory depression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other findings, including hyporeflexia, hypothermia, dermal "track marks", flushing, pruritus, bradycardia, hypotension, or decreased bowel sounds
        </p>
        <p>
        </p>
        <p>
         Opioids can also cause multiple physical findings in various organ systems:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pupillary response
         </strong>
         – Miosis (pupillary constriction) usually occurs within five minutes of intravenous administration and lasts for at least six hours [
         <a href="#rid48">
          48
         </a>
         ]. Although miosis is the usual finding, mydriasis or normal pupils may be seen with overdose of
         <a class="drug drug_pediatric" data-topicid="12580" href="/z/d/drug information/12580.html" rel="external">
          meperidine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         (rarely), propoxyphene,
         <a class="drug drug_pediatric" data-topicid="13220" href="/z/d/drug information/13220.html" rel="external">
          dextromethorphan
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12692" href="/z/d/drug information/12692.html" rel="external">
          pentazocine
         </a>
         , in the early stages of
         <a class="drug drug_pediatric" data-topicid="13237" href="/z/d/drug information/13237.html" rel="external">
          diphenoxylate-atropine
         </a>
         (Lomotil poisoning), and after the use of
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         [
         <a href="#rid38">
          38,54,55
         </a>
         ]. Mydriasis or normal pupils also may be seen if heroin was coingested with a stimulant or anticholinergic drug, such as cocaine (ie, "speedball") or
         <a class="drug drug_pediatric" data-topicid="16045" href="/z/d/drug information/16045.html" rel="external">
          scopolamine
         </a>
         , or if hypoxic brain injury occurred because of prolonged respiratory depression [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Respiratory depression and noncardiogenic pulmonary edema
         </strong>
         – Most opioid-related deaths are caused by respiratory depression, which is caused by central and peripheral effects. Respiratory depression may be subtle. The isolated respiratory rate is not a reliable measure of ventilation because a small decrease in tidal volume occurs before the respiratory rate declines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Noncardiogenic pulmonary edema may complicate opioid overdose. The characteristic findings include pink, frothy bronchial secretions, cyanosis, and rales in a stuporous or comatose patient with respiratory depression and miotic pupils. The distribution of pulmonary edema on chest radiograph usually is nonuniform [
         <a href="#rid56">
          56
         </a>
         ]. The pathophysiology of this form of pulmonary edema is not known. Proposed mechanisms include forceful inspiration (negative pressure) against a closed glottis, direct toxicity of the drug, hypoxia, and acidosis secondary to hypoventilation and/or cerebral edema. Resolution of pulmonary edema is rapid once assisted ventilation is instituted and both hypoventilation and hypoxia are reversed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The incidence of noncardiogenic pulmonary edema in patients hospitalized with heroin overdose is 48 to 80 percent [
         <a href="#rid57">
          57
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          Methadone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         , and propoxyphene also can cause noncardiogenic pulmonary edema. The interval between exposure and symptom onset usually is less than two hours for heroin-related cases [
         <a href="#rid56">
          56
         </a>
         ] and less than 6 to 12 hours for those associated with methadone. Some case reports have suggested that
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         itself precipitates noncardiogenic pulmonary edema in patients with opioid overdose. However, alveolar filling was noted on autopsy in 50 to 90 percent of heroin overdose patients that did not receive naloxone [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular
         </strong>
         – Opioids cause bradycardia and hypotension via increased parasympathetic activity, decreased sympathetic activity, and release of histamine brought about by their effects on the vasomotor center [
         <a href="#rid59">
          59
         </a>
         ]. The drug-induced bradycardia and increased automaticity can cause arrhythmia, including potentially lethal ventricular tachyarrhythmia [
         <a href="#rid60">
          60
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          Methadone
         </a>
         , in particular, can block the inwardly rectifying potassium current with subsequent prolongation of the QT interval [
         <a href="#rid61">
          61
         </a>
         ]. According to case reports, heroin contaminated with clenbuterol, a beta2 agonist, has resulted in tachycardia [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic
         </strong>
         – Patients presenting to the emergency department typically are stuporous or comatose. Patients with profound CNS depression are at risk for aspiration of gastric contents because of impaired gag reflex and centrally mediated nausea and vomiting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Generalized seizures can occur after intravenous
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12812" href="/z/d/drug information/12812.html" rel="external">
          sufentanil
         </a>
         administration, the prolonged use of
         <a class="drug drug_pediatric" data-topicid="12580" href="/z/d/drug information/12580.html" rel="external">
          meperidine
         </a>
         , and large ingestions of propoxyphene,
         <a class="drug drug_pediatric" data-topicid="12892" href="/z/d/drug information/12892.html" rel="external">
          tramadol
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12692" href="/z/d/drug information/12692.html" rel="external">
          pentazocine
         </a>
         [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A Parkinsonian-like syndrome has been associated with some opioid-based designer drugs, such as MPTP (1, methyl, 4 phenyl 1,2,3,6 tetrahydropyridine) [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal
         </strong>
         – Constipation results from decreased motility and increased sphincter tone in the rectum. The classic recommendation that
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         should not be used in the treatment of biliary colic was based upon the long-standing teaching that morphine causes spasm of the sphincter of Oddi. However, no significant differences in intrabiliary pressures were found in clinical studies comparing morphine and
         <a class="drug drug_pediatric" data-topicid="12580" href="/z/d/drug information/12580.html" rel="external">
          meperidine
         </a>
         [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Muscle rigidity and rhabdomyolysis
         </strong>
         – All opioid agonists can produce skeletal muscle rigidity, even at low doses [
         <a href="#rid65">
          65
         </a>
         ]. Acute rhabdomyolysis and renal failure may occur with the use of heroin,
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         , and propoxyphene.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin
         </strong>
         –
         <strong>
         </strong>
         Track marks can be seen frequently in those opioid users who routinely use the intravenous route for injection. Those injecting drug subcutaneously ("skin poppers") may be at risk for wound botulism. (See
         <a class="medical medical_review" href="/z/d/html/5509.html" rel="external">
          "Botulism", section on 'Types of botulism and their sources'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reproductive
         </strong>
         – In girls, opioids may cause amenorrhea, anovulatory cycles, and impaired fertility caused by abnormal prolactin secretion secondary to the opioid action on the dopaminergic system. In addition, opioids may cause decreased libido in both males and females [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endocrine
         </strong>
         – Hypoketotic hypoglycemia with hyperinsulinism has been described in one toddler after unintentional exposure to
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H886660">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In adolescents, the differential diagnosis for opioid intoxication is similar to adults. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
         In children under six years of age, common toxicologic causes of coma include benzodiazepines and other sedative-hypnotic agents, alpha-2 receptor agonists (eg,
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         , xylazine), oral hypoglycemic agents, ethanol, psychotropic medications, and exposure to carbon monoxide  (
         <a class="graphic graphic_table graphicRef80618" href="/z/d/graphic/80618.html" rel="external">
          table 4
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         While
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         may produce miosis and obtundation, bradycardia, and hypotension are more prominent than in patients with opioid intoxication. Xylazine, an alpha-2 receptor agonist (similar to clonidine) used as a veterinary sedative, can be found in illicit heroin and
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         . It can also cause miosis, obtundation, bradycardia, and hypotension that is not reversed by
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         , and with repeat parenteral use, can lead to severe, necrotic skin ulcerations. (See
         <a class="medical medical_review" href="/z/d/html/6509.html" rel="external">
          "Clonidine, xylazine, and related imidazoline poisoning", section on 'Xylazine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ethanol intoxication produces little to no miosis and no change in bowel sounds. Nystagmus and hypoglycemia may be prominent features in young children. (See
         <a class="medical medical_review" href="/z/d/html/6487.html" rel="external">
          "Ethanol intoxication in children: Clinical features, evaluation, and management", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The sedative-hypnotic agents and gabapentinoids result in much less respiratory depression than the opioids, especially when taken orally. Pupils are typically not pinpoint, and ataxia may be a prominent feature in children. (See
         <a class="medical medical_review" href="/z/d/html/314.html" rel="external">
          "Benzodiazepine poisoning", section on 'Clinical features of overdose'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139762.html" rel="external">
          "Gabapentinoid poisoning and withdrawal", section on 'Clinical features of overdose'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Organophosphate-containing substances may cause miosis and coma in children but are also accompanied by prominent parasympathetic and preganglionic sympathetic symptoms (eg, vomiting, diarrhea, sweating, bronchorrhea, salivation, bradycardia or tachycardia, hypo- or hypertension), fasciculations and paralysis. (See
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Acute toxicity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">
          Baclofen
         </a>
         , a gamma-aminobutyric acid (GABA) B receptor agonist, can cause coma, respiratory depression, bradycardia, and hypotension after ingestion in children and adolescents [
         <a href="#rid68">
          68,69
         </a>
         ]. Myoclonus and seizures can occur. (See
         <a class="medical medical_review" href="/z/d/html/141081.html" rel="external">
          "GABA-B agonist (baclofen, phenibut) poisoning and withdrawal", section on 'Clinical features of overdose'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Any medical condition that causes coma may mimic opioid poisoning in children. Key conditions to exclude are those in which delayed diagnosis also delays specific care, such as hypoxemia, hypoglycemia, sepsis, central nervous system (CNS) infection, and abusive head trauma. (See
         <a class="medical medical_review" href="/z/d/html/6225.html" rel="external">
          "Evaluation of stupor and coma in children", section on 'Etiologies'
         </a>
         .)
        </p>
        <p>
         Intussusception may present with coma and miosis, and CNS depression associated with intussusception may respond to
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         therapy, presumably due to elaboration of endogenous endorphins.
        </p>
        <p class="headingAnchor" id="H886681">
         <span class="h1">
          ANCILLARY STUDIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children and adolescents with altered mental status and suspected opioid intoxication warrant the following studies  (
         <a class="graphic graphic_table graphicRef69375" href="/z/d/graphic/69375.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood glucose
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulse oximetry and, if respiratory status does not improve after
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         administration, blood gas measurement
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         concentration if suicidal intent or if ingestion of combination agents (eg, acetaminophen with
         <a class="drug drug_general" data-topicid="91299" href="/z/d/drug information/91299.html" rel="external">
          hydrocodone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12666" href="/z/d/drug information/12666.html" rel="external">
          oxycodone
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum ethanol level (adolescents with recreational or suicidal overdose)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrocardiogram, especially in patients with
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         overdose to evaluate for prolonged QTc
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest radiograph, in patients with persistent respiratory findings suggestive of pulmonary aspiration or noncardiogenic pulmonary edema
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid urine pregnancy test in postmenarcheal girls
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinalysis, serum electrolytes, blood urea nitrogen, creatinine, and creatine kinase in patients at risk for rhabdomyolysis (eg, prolonged immobilization, muscular rigidity)
        </p>
        <p>
        </p>
        <p>
         Further laboratory evaluation of opioid overdose varies depending upon the circumstances of exposure. A witnessed exploratory ingestion in a toddler or a known recreational overdose with full recovery after antidotal therapy may merit little laboratory investigation whereas an unwitnessed suicidal overdose may lead to more extensive testing, especially if the patient displays persistent symptoms despite antidotal therapy or has evidence of serious coingestants. Other ancillary studies may be indicated in selected patients in whom trauma, infection, or other etiologies besides poisoning are suspected. (See
         <a class="medical medical_review" href="/z/d/html/6225.html" rel="external">
          "Evaluation of stupor and coma in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">
          "Approach to the child with occult toxic exposure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Testing for opioids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rapid enzyme-mediated immunoassay technique (EMIT), mass spectrophotometry, gas chromatography, and radioimmunoassay are available to test urine for opioids. However, the results of these tests require interpretation based upon the clinical scenario for a number of reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          False-positive results
         </strong>
         – The metabolites of some medications and foods are the same as the metabolites of opioids of abuse (eg,
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         with
         <a class="drug drug_pediatric" data-topicid="13178" href="/z/d/drug information/13178.html" rel="external">
          codeine
         </a>
         , codeine cough syrup, and poppy seeds). In addition, fluoroquinolones have been described as a cause for false positive opiate screens [
         <a href="#rid70">
          70,71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          False-negative results
         </strong>
         – Some synthetic opioids (eg,
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         ) do not contain the phenanthrene nucleus that is needed for detection on typical commercially obtained hospital toxicology screens for opioids. Furthermore, tampering methods or dilute samples may interfere with actual toxicology screening results [
         <a href="#rid72">
          72,73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urine detection
         </strong>
         – Opioids are detectable in the urine for only two to four days after use. (See
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In an adolescent with a known recreational exposure to opioids who responds to antidotal therapy, the diagnosis is confirmed. Urine toxicologic testing does not add anything further to acute clinical management and is not recommended. However, healthcare providers involved in adolescent substance use disorder treatment programs may utilize toxicology screening results to further enhance outpatient therapy [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         In children under six years of age in whom the cause of coma is unknown or in whom malicious administration of opioids is suspected, the most accurate form of testing (eg, gas chromatography mass spectrophotometry, or GCMS), may be indicated to definitively document the exposure for legal reasons.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          MANAGEMENT OF ACUTE TOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         A rapid overview provides a summary for the evaluation and treatment of opioid overdose  (
         <a class="graphic graphic_table graphicRef69375" href="/z/d/graphic/69375.html" rel="external">
          table 3
         </a>
         ). Most of the direct morbidity and mortality related to opiate use occur after acute ingestion and are caused by hypoxemia, aspiration pneumonitis, pulmonary edema, acute respiratory acidosis, and anaphylaxis. Immediate management involves airway management and administration of an opioid antagonist  (
         <a class="graphic graphic_table graphicRef69375" href="/z/d/graphic/69375.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients whose respiratory status is compromised should be supported with bag mask ventilation and 100 percent oxygen while the opioid antagonist,
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         , is administered [
         <a href="#rid75">
          75
         </a>
         ]. They may require supplemental oxygen, endotracheal intubation, and positive end expiratory pressure if there is inadequate response to naloxone or if pulmonary edema is present. If endotracheal intubation has been performed, and mechanical ventilation is being administered, then naloxone administration may be counterproductive.
        </p>
        <p>
         Glucose should be administered intravenously if indicated by immediate bed-side glucose testing (&lt;60 mg/dL). (See
         <a class="medical medical_review" href="/z/d/html/5805.html" rel="external">
          "Approach to hypoglycemia in infants and children", section on 'Glucose therapy'
         </a>
         .)
        </p>
        <p>
         Seizures and cardiac dysrhythmias occur rarely and should be managed with standard therapies. (See
         <a class="medical medical_review" href="/z/d/html/6222.html" rel="external">
          "Clinical features and complications of status epilepticus in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23953471">
         <span class="h2">
          Body packers and stuffers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment, including recommendations for activated charcoal administration and initiation of whole bowel irrigation in body packers or body stuffers, is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Body packing and body stuffing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/327.html" rel="external">
          "Internal concealment of drugs of abuse (body packing)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Gastrointestinal decontamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend administration of activated charcoal (AC, 1 g/kg PO or NG with a maximum of 50 g) to alert young children and adolescents who have ingested opioids and who present within one hour of oral overdose. In patients with altered mental status, activated charcoal administration should be delayed until reversal of symptoms with
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         has restored consciousness or the airway has been secured. Alternatively, AC may be withheld in such patients if toxicity is well-controlled with naloxone and the presence of unabsorbed opioid medication is unlikely. Patients who have orally ingested large amounts of opioids (body stuffers or packers), sustained release opioids, or opioid patch medications should receive gastrointestinal decontamination with AC and whole bowel irrigation as described separately. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Body packing and body stuffing'
         </a>
         .)
        </p>
        <p>
         This recommendation for activated charcoal administration following oral opioid overdose derives from indirect evidence of benefit in volunteers, animal studies, and evidence of benefit following ingestions of other medications. Opioids, like most other xenobiotics, bind well to activated charcoal.
         <a class="drug drug_pediatric" data-topicid="12801" href="/z/d/drug information/12801.html" rel="external">
          Sorbitol
         </a>
         is an osmotically active carbohydrate often used to sweeten activated charcoal and to speed its intestinal transit: evidence for benefit from sorbitol is scant and it should not be used for more than a single dose of activated charcoal. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient", section on 'Cathartics'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient", section on 'Evidence of efficacy and adverse effects'
         </a>
         .)
        </p>
        <p>
         The greatest benefit occurs if AC is given within one hour. The efficacy of AC as a function of time from ingestion is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'
         </a>
         .)
        </p>
        <p>
         AC administration is not indicated following intravenous or inhalational opioid overdose.
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Naloxone
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          Naloxone
         </a>
         is a synthetic derivative of
         <a class="drug drug_general" data-topicid="9733" href="/z/d/drug information/9733.html" rel="external">
          oxymorphone
         </a>
         that competitively binds opioid receptors and is the antagonist of choice for reversal of acute opioid toxicity [
         <a href="#rid76">
          76
         </a>
         ]. It has a greater affinity for the mu receptors than do opioid agonists; for example, the effects of 25 mg of heroin are blocked by 1 mg of naloxone. Naloxone is highly lipophilic, moves rapidly into the central nervous system, and has an onset of action of one minute when given intravenously [
         <a href="#rid76">
          76
         </a>
         ]. Clinical effects of naloxone typically last 45 to 70 minutes.
        </p>
        <p class="headingAnchor" id="H18254225">
         <span class="h3">
          Dosing and administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend that children and adolescents with clinical findings of coma, depressed respirations and miosis or circumstantial evidence of opioid abuse receive
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         rather than supportive care alone. Although the greatest amount of evidence supporting naloxone use for opioid intoxication is derived from adult studies, observational studies and case reports in children have also shown that naloxone effectively reverses severe opioid poisoning with minimal adverse effects [
         <a href="#rid24">
          24,77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Basic measures and antidotal therapy'
         </a>
         and
         <a class="local">
          'Adverse effects'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose
         </strong>
         – The dose of
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         for serious opioid intoxication varies depending upon the size of the patient and the clinical scenario  (
         <a class="graphic graphic_table graphicRef69375" href="/z/d/graphic/69375.html" rel="external">
          table 3
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children &lt;20 kg should receive
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         0.1 mg/kg IV (maximum 2 mg per dose). The use of naloxone in neonates in the delivery room is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5015.html" rel="external">
          "Neonatal resuscitation in the delivery room", section on 'Naloxone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children ≥20 kg should receive
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         2 mg IV.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adolescents suspected of opioid dependence who are breathing spontaneously should receive an initial dose of 0.04 mg IV, and the dose should be titrated upward every few minutes until the respiratory rate is 12 or greater to avoid iatrogenic opioid withdrawal [
         <a href="#rid75">
          75,78
         </a>
         ]. A common approach is to dilute 1 mL of a
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         0.4 mg/mL formulation with 9 mL of normal
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         or sterile water for injection (creating a total volume of 10 mL with a 0.04 mg/mL concentration) and administering 1 to 2 mL aliquots. Apneic adolescents should receive higher initial doses of naloxone (0.2 to 1 mg), while those in cardiorespiratory arrest following possible opioid overdose should be given a minimum of 2 mg of naloxone [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          Naloxone
         </a>
         should be repeated every few minutes until improvement in respiratory depression is noted. Cumulative doses of naloxone great than 10 mg in the first half hour are unlikely to yield additional benefit. Larger than customary doses of naloxone may be required to reverse the effects of drugs with higher receptor affinity than
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         (eg,
         <a class="drug drug_pediatric" data-topicid="13178" href="/z/d/drug information/13178.html" rel="external">
          codeine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13237" href="/z/d/drug information/13237.html" rel="external">
          diphenoxylate-atropine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         , fentanyl analogs, propoxyphene,
         <a class="drug drug_pediatric" data-topicid="12692" href="/z/d/drug information/12692.html" rel="external">
          pentazocine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12627" href="/z/d/drug information/12627.html" rel="external">
          nalbuphine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12918" href="/z/d/drug information/12918.html" rel="external">
          buprenorphine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9179" href="/z/d/drug information/9179.html" rel="external">
          butorphanol
         </a>
         ) [
         <a href="#rid76">
          76
         </a>
         ]. If respiratory depression of unknown etiology has failed to improve with a cumulative dose of 10 mg of naloxone, then isolated opioid toxicity is unlikely.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Route of administration
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          Naloxone
         </a>
         is preferably administered intravenously. However, it can also be administered intranasally, intramuscularly, subcutaneously, endotracheally, or intralingually (ie, injected into the sublingual vein) as well as via an intraosseous needle [
         <a href="#rid76">
          76,81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of recurrent toxicity
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          Naloxone
         </a>
         has a shorter duration of action (one-half to one hour) than do most opioids and may need to be administered as repeated boluses or continuous infusion until full opioid metabolism has occurred. As an example, children with
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         overdose may require naloxone therapy for several days [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Continuous infusions of
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         have been used safely in children [
         <a href="#rid82">
          82,83
         </a>
         ]. Naloxone should be mixed in a solution of 5 percent dextrose OR normal
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         and infused at a rate that does not exceed the hourly maintenance rate for weight. (See
         <a class="medical medical_review" href="/z/d/html/6122.html" rel="external">
          "Maintenance intravenous fluid therapy in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One method for administering a constant infusion is as follows [
         <a href="#rid84">
          84
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Determine the amount of
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         that was required to restore respiratory function during bolus dosing. Two-thirds of this dose is then administered as an hourly infusion. Care must be taken to avoid induction of withdrawal symptoms in patients who are opioid dependent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A transient drop in
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         levels may occur 20 to 30 minutes after the continuous infusion is initiated. To prevent this from occurring, one-half of the loading dose (the dose required to reverse respiratory depression) should be administered 15 minutes after the continuous infusion is started [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The rate of infusion should be titrated to maintain respiration and avoid withdrawal symptoms. Respiratory and mental status must be closely monitored.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The infusion rate may be decreased by 50 percent every hour for the next 6 to 12 hours (the duration of action of most opiates). The
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         infusion should be continued until complete or near complete reversal of the respiratory depression occurs.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18254252">
         <span class="h3">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Precipitation of opioid withdrawal by
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         administration is the most common adverse effect. Although withdrawal is not life-threatening except in the neonatal period, the agitation, nausea, vomiting, and anxiety are distressing to the patient. Patients in acute withdrawal may become violent, potentially causing harm to themselves or healthcare providers [
         <a href="#rid85">
          85
         </a>
         ]. Symptoms typically subside 20 to 30 minutes after the administration of naloxone because the antagonist effect diminishes. Incremental low dosing of naloxone in patients with suspected opioid use disorder is the main way to avoid withdrawal.
        </p>
        <p>
         Rare complications possibly attributable to
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         therapy of opioid intoxication and reported in adults include pulmonary edema, hypertension, hypotension, dysrhythmia, and sudden death [
         <a href="#rid76">
          76,86,87
         </a>
         ]. No sudden death attributable to naloxone has been reported in children outside of the neonatal period.
        </p>
        <p class="headingAnchor" id="H18253698">
         <span class="h3">
          Other opioid antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          Naloxone
         </a>
         is the preferred drug for acute treatment of opioid intoxication. Other longer acting opioid antagonists have been occasionally used as acute therapy in adults, instead of naloxone infusion in patients with prolonged intoxication, and for long-term opioid detoxification:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nalmefene
         </strong>
         <strong>
         </strong>
         –
         <a class="drug drug_general" data-topicid="135038" href="/z/d/drug information/135038.html" rel="external">
          Nalmefene
         </a>
         has a longer duration of action than that of
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         . Its use in the acute care setting is controversial. Compared with naloxone, it causes fewer fluctuations in the patient's level of consciousness and decreased risk for recurrent opioid toxicity in patients who leave against medical advice soon after initial resuscitation. On the other hand, nalmefene may precipitate prolonged withdrawal in patients with opioid use disorder or recurrent symptoms in patients who have taken synthetic opioids with duration of action equal to or longer than that of nalmefene [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="135038" href="/z/d/drug information/135038.html" rel="external">
          Nalmefene
         </a>
         may be considered for use in children who have had a single opioid exposure or in those who are being admitted to the hospital and do not experience withdrawal after a trial dose of
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         [
         <a href="#rid88">
          88
         </a>
         ]. Nalmefene may also be used safely in potentially opioid-dependent adolescents after a trial dose of naloxone has been tolerated safely. Intravenous doses of 0.5 to 2 mg have been reported to be safe and effective in adults. The duration of action is 4 to 10 hours if the dose is 0.5 to 1 mg, and greater than 8 hours if the dose is 2 mg. Adverse effects of nalmefene are uncommon and include nausea and vomiting, tachycardia, myoclonus, dizziness, and drowsiness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although the optimal
         <a class="drug drug_general" data-topicid="135038" href="/z/d/drug information/135038.html" rel="external">
          nalmefene
         </a>
         dose for pediatric opioid overdose has not been studied, intravenous doses of 0.25 to 1 mcg/kg (to a maximum of 40 mcg) have been safely used to reverse sedation in 15 pediatric patients [
         <a href="#rid89">
          89
         </a>
         ]. An intranasal formulation of nalmefene (2.7 mg dose) is also approved in the United States for acute opioid intoxication in adolescents and adults.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Naltrexone
         </strong>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          Naltrexone
         </a>
         is an oral opioid antagonist with a longer duration of action than that of
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         . It is used primarily to promote long-term opioid abstinence. Naltrexone is not indicated in the treatment of acute opioid toxicity because it is administered orally and because it can induce a prolonged withdrawal state [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H887418">
         <span class="h2">
          Child protection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In cases where child abuse is suspected, involvement of an experienced child protection team is crucial and in many parts of the world (including the United States, United Kingdom, and Australia) reporting to a governmental agency is mandatory. The safety of other children in the home must be ensured by local Child Protective Services. (See
         <a class="medical medical_review" href="/z/d/html/6604.html" rel="external">
          "Child abuse: Social and medicolegal issues", section on 'Reporting suspected abuse'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6600.html" rel="external">
          "Physical child abuse: Diagnostic evaluation and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h2">
          Disposition
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following patients warrant hospital admission:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infants and young children who require
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         administration to reverse opioid effects or in whom intentional poisoning by the caretaker is suspected.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients in whom delayed or prolonged opioid intoxication is likely (eg, ingestion of
         <a class="drug drug_pediatric" data-topicid="13237" href="/z/d/drug information/13237.html" rel="external">
          diphenoxylate-atropine
         </a>
         [Lomotil],
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12918" href="/z/d/drug information/12918.html" rel="external">
          buprenorphine
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who are suicidal or whose social setting does not provide a safe environment for the child.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adolescents who have recurrence of respiratory depression or noncardiogenic pulmonary edema. As in adults, recurrent symptoms of intoxication or respiratory distress should be evident within two hours of initial treatment and observation beyond that time is not necessary. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Disposition'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         For adolescent patients in whom opioid use disorder is identified, the plans for long-term management of the drug problem and referrals to local substance abuse treatment resources should be made before discharge. (See
         <a class="medical medical_review" href="/z/d/html/120005.html" rel="external">
          "Substance use disorder in adolescents: Treatment overview"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H886898">
         <span class="h1">
          COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many of the complications of opioid use are related to the method of administration. Snorting is associated with chronic rhinitis and septal ulcers with disintegration. Smoking can cause burns and exacerbate preexisting asthma and respiratory illnesses. Intravenous administration is associated with many complications  (
         <a class="graphic graphic_table graphicRef69983" href="/z/d/graphic/69983.html" rel="external">
          table 5
         </a>
         ), including bacterial endocarditis, blood-borne infection, septic pulmonary emboli, nephropathy, abscesses, and cellulitis [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Opioid adulterants, including krokodil'
         </a>
         .)
        </p>
        <p>
         Opioid use impairs judgment and can put the user at risk for unintentional injury. One-tenth of the adolescent trauma victims in one emergency department had urine toxicology screens that were positive for opioids [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
         The social and behavioral consequences of opioid use disorder are influenced by the lifestyle of drug dependence. Adolescents who use opioids typically are involved in other high-risk behaviors (eg, polysubstance abuse, high-risk sexual practices, delinquency, and school failure). These adolescents often run away from home or become homeless. They may resort to prostitution, robbery, or burglary to obtain drugs or money for drugs. In addition, adolescent substance use disorder is a significant risk for violence-related injury. (See
         <a class="medical medical_review" href="/z/d/html/593.html" rel="external">
          "Peer violence and violence prevention", section on 'Adolescent screening'
         </a>
         .)
        </p>
        <p>
         The life-threatening effects of opioids are related to respiratory failure and failure of physiological oxygen delivery. Ischemic injury to the brain, heart, and other body organs are dire complications of opioid poisoning.
        </p>
        <p class="headingAnchor" id="H509033305">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although evidence is limited regarding specific strategies that health care providers can follow to prevent opioid intoxication in children and adolescents, observational studies identify the following activities for emphasis:
        </p>
        <p class="headingAnchor" id="H1127821965">
         <span class="h2">
          Safe storage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Health care providers should advise that all prescription opioid medications be kept in a secured location at home (eg, locked cabinet).
        </p>
        <p>
         This recommendation is based upon national trends that implicate prescription opioids as a frequent source of opioid intoxication and deaths in children and adolescents and a driver of opioid dependence and opioid use disorder. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">
          "Prescription drug misuse: Epidemiology, prevention, identification, and management", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
         Despite these trends, preliminary evidence suggests that safe storage is uncommon. For example, in a nationally representative survey of 1032 adults with prescription opioid use in the past 12 months, only 9 percent reported safe storage of their medications [
         <a href="#rid92">
          92
         </a>
         ]. Furthermore, of the 681 adults in this survey who had children younger than 18 years of age in the household, safe storage was reported in only 29 to 33 percent of households with young children and 12 percent of households with children older than six years of age [
         <a href="#rid93">
          93
         </a>
         ]. Safe storage was more likely among adults with younger children who worried about their child’s access to the drugs and who were certain that they could store medications in a locked location at all times.
        </p>
        <p>
         These surveys support public health campaigns and anticipatory guidance by health care providers that emphasize how safe storage may reduce opioid overdose and limit opioid misuse (ie, opioid abuse, or diversion) in children and adolescents. Further research should focus on developing and implementing effective means of secure storage in households.
        </p>
        <p class="headingAnchor" id="H2724862917">
         <span class="h2">
          Safe prescribing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Health care providers should follow guidance for safe prescribing developed by the Centers for Disease Control and Prevention [
         <a href="#rid94">
          94
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When treating pain in children and adolescents, health care providers should discuss therapeutic options with the caregiver and patient, including treatments other than prescription opioids. In one study in which children without major chronic diseases were prescribed opioids as an outpatient, one of every 2611 study opioid prescriptions was followed by an opioid-related adverse event (71.2 percent were related to therapeutic use) [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Health care providers should use prescription drug monitoring programs, where available, to identify patients or caregivers who might be misusing (ie, abusing or diverting) prescription opioid medications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When indicated, providers should prescribe the lowest effective dose and minimum quantity of prescription opioid medications. When not contraindicated,
         <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">
          acetaminophen
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">
          ibuprofen
         </a>
         should also be used to decrease the amount of opioid medication required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concurrent prescription of sedatives with opioids should be
         <strong>
          avoided
         </strong>
         .
        </p>
        <p>
        </p>
        <p>
         Long term trends based upon surveys of high school seniors in the United States over 40 years show that the use of prescription opioids is strongly correlated with misuse in adolescents and that misuse typically follows medical use by the patient [
         <a href="#rid96">
          96
         </a>
         ]. In adults, greater daily opioid doses and greater numbers of prescriptions per month are associated with a higher risk of overdose death. (See
         <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">
          "Prescription drug misuse: Epidemiology, prevention, identification, and management", section on 'Limiting exposure'
         </a>
         .)
        </p>
        <p>
         Thus, safe prescribing habits may have a significant impact on reducing opioid intoxication although further study is needed to document their impact.
        </p>
        <p class="headingAnchor" id="H7471870">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H1233887230">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3529424939">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113643.html" rel="external">
          "Society guideline links: Opioid use disorder and withdrawal"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112688.html" rel="external">
          "Society guideline links: Poisoning prevention"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114015.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by recreational drug or alcohol use"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H886958">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rapid overview
         </strong>
         – A rapid overview provides clinical features, recommended ancillary studies, and suggested management of opioid intoxication in children and adolescents  (
         <a class="graphic graphic_table graphicRef69375" href="/z/d/graphic/69375.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Opioid intoxication in adolescents primarily results from recreational use or intentional exposure with suicidal intent. In young children, opioid poisoning typically occurs following exploratory ingestion, although the possibility of malicious exposure by a caretaker should be evaluated. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations and diagnosis
         </strong>
         – The diagnosis of opioid intoxication is usually made based upon clinical findings. The classic signs of opioid intoxication include depressed mental status, decreased respiratory rate, decreased tidal volume, decreased bowel sounds, and miotic pupils. The best predictor of opioid poisoning is respiratory depression. Normal pupil examination or mydriasis does
         <strong>
          not
         </strong>
         exclude opioid intoxication. (See
         <a class="local">
          'Physical examination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Any medical condition that causes coma may mimic opioid poisoning in children. Key conditions to exclude are those in which delayed diagnosis also delays specific care, such as hypoxemia, hypoglycemia, sepsis, central nervous system infection, and abusive head trauma. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Management of opioid intoxication includes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Support airway, breathing, and circulation
         </strong>
         – Support of the child’s airway and breathing using bag-mask ventilation with 100 percent inspired oxygen until an opioid antagonist is administered. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          Naloxone
         </a>
         – We recommend that children and adolescents with suspected opioid overdose receive naloxone rather than supportive care alone (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). The first dose of naloxone varies depending upon the size of the patient and the clinical scenario (see
         <a class="local">
          'Dosing and administration'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Children &lt;20 kg: 0.1 mg/kg IV (maximum 2 mg per dose).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Children ≥20 kg: 2 mg IV.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Adolescents with suspected opioid dependence and spontaneous ventilation should receive lower doses of
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         (similar to adult treatment strategy) to avoid precipitation of opioid withdrawal  (
         <a class="graphic graphic_table graphicRef55540" href="/z/d/graphic/55540.html" rel="external">
          table 6
         </a>
         ). A naloxone dose of 0.04 mg is an appropriate starting point, and the dose should be titrated upward every few minutes until the respiratory rate is 12 or greater. May dilute 1 mL of a naloxone 0.4 mg/mL formulation with 9 mL of normal
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         or sterile water for injection (creating a total volume of 10 mL with a 0.04 mg/mL concentration) and administer 1 to 2 mL aliquots. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Basic measures and antidotal therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The use of
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         in neonates is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5015.html" rel="external">
          "Neonatal resuscitation in the delivery room", section on 'Naloxone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gastrointestinal decontamination
         </strong>
         – We recommend administration of activated charcoal (1 g/kg PO or NG with a maximum of 50 g) to alert young children and adolescents who have ingested opioids and who present within one hour of overdose (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Activated charcoal administration is not indicated following intravenous or inhalational opioid overdose. (See
         <a class="local">
          'Gastrointestinal decontamination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Beyond one hour of overdose, patients who have orally ingested large amounts of opioids (body stuffers or packers), sustained release opioids, or opioid patch medications may warrant whole bowel irrigation as described separately. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Body packing and body stuffing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/327.html" rel="external">
          "Internal concealment of drugs of abuse (body packing)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disposition
         </strong>
         – The following patients warrant hospitalization after opioid intoxication (see
         <a class="local">
          'Disposition'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infants and young children who require
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         administration to reverse opioid effects or in whom intentional poisoning by the caretaker is suspected.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients in whom delayed or prolonged opioid intoxication is likely (eg, ingestion of
         <a class="drug drug_pediatric" data-topicid="13237" href="/z/d/drug information/13237.html" rel="external">
          diphenoxylate-atropine
         </a>
         [Lomotil],
         <a class="drug drug_pediatric" data-topicid="12590" href="/z/d/drug information/12590.html" rel="external">
          methadone
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12918" href="/z/d/drug information/12918.html" rel="external">
          buprenorphine
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who are suicidal or whose social setting does not provide a safe environment for the child.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adolescents who have recurrence of respiratory depression or noncardiogenic pulmonary edema. As in adults, recurrent symptoms of intoxication or respiratory distress should be evident within two hours of initial treatment and observation beyond that time is not necessary. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Disposition'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Child protection
         </strong>
         – In cases of suspected child abuse, perform further evaluation  (
         <a class="graphic graphic_table graphicRef119442" href="/z/d/graphic/119442.html" rel="external">
          table 7
         </a>
         ), preferably in consultation with a multidisciplinary children protection team (if available) and report suspicion to the appropriate governmental agency. (See
         <a class="medical medical_review" href="/z/d/html/6600.html" rel="external">
          "Physical child abuse: Diagnostic evaluation and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Referral for opioid use disorder
         </strong>
         – For adolescent patients in whom opioid use disorder is identified, the plans for long-term management of the drug problem and referrals to local substance abuse treatment resources should be made before discharge. (See
         <a class="medical medical_review" href="/z/d/html/120005.html" rel="external">
          "Substance use disorder in adolescents: Treatment overview"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hibbs J, Perper J, Winek CL. An outbreak of designer drug--related deaths in Pennsylvania. JAMA 1991; 265:1011.
          </a>
         </li>
         <li class="breakAll">
          Recommendations for laboratory testing for acetyl fentanyl and patient evaluation and treatment for overdose with synthetic opioids. Health Alert Network Centers for Disease Control health advisory. June 20, 2013. Accessed at www.bt.cdc.gov/HAN/han00350.asp on July 16, 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brittain JL. China white: the bogus drug. J Toxicol Clin Toxicol 1982; 19:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985; 35:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis GC, Williams AC, Markey SP, et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979; 1:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219:979.
          </a>
         </li>
         <li class="breakAll">
          European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System (December 2020). Publications Office of the European Union, Luxembourg, 2020. https://www.emcdda.europa.eu/system/files/publications/13464/20205648_TD0320796ENN_PDF_rev.pdf (Accessed on March 01, 2023).
         </li>
         <li class="breakAll">
          DEA issues carfentanil warning to police and public. https://www.dea.gov/divisions/hq/2016/hq092216.shtml (Accessed on November 07, 2016).
         </li>
         <li class="breakAll">
          Opium/heroin. Drug statistics and trends. World Drug Report, 2009, United Nations Office on Drugs and Crimes. www.unodc.org/documents/wdr/WDR_2010/2.2_Opium-heroin.pdf (Accessed on June 01, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363:1981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mack KA, Jones CM, Ballesteros MF. Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas - United States. MMWR Surveill Summ 2017; 66:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaither JR, Shabanova V, Leventhal JM. US National Trends in Pediatric Deaths From Prescription and Illicit Opioids, 1999-2016. JAMA Netw Open 2018; 1:e186558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaither JR. National Trends in Pediatric Deaths From Fentanyl, 1999-2021. JAMA Pediatr 2023; 177:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaither JR, Leventhal JM, Ryan SA, Camenga DR. National Trends in Hospitalizations for Opioid Poisonings Among Children and Adolescents, 1997 to 2012. JAMA Pediatr 2016; 170:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCabe SE, West BT, Teter CJ, Boyd CJ. Medical and nonmedical use of prescription opioids among high school seniors in the United States. Arch Pediatr Adolesc Med 2012; 166:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yokell MA, Delgado MK, Zaller ND, et al. Presentation of prescription and nonprescription opioid overdoses to US emergency departments. JAMA Intern Med 2014; 174:2034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen JD, Casavant MJ, Spiller HA, et al. Prescription Opioid Exposures Among Children and Adolescents in the United States: 2000-2015. Pediatrics 2017; 139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011; 12:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayes BD, Klein-Schwartz W, Doyon S. Toxicity of buprenorphine overdoses in children. Pediatrics 2008; 121:e782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sachdeva DK, Stadnyk JM. Are one or two dangerous? Opioid exposure in toddlers. J Emerg Med 2005; 29:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geib AJ, Babu K, Ewald MB, Boyer EW. Adverse effects in children after unintentional buprenorphine exposure. Pediatrics 2006; 118:1746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin TC, Rocque MA. Accidental and non-accidental ingestion of methadone and buprenorphine in childhood: a single center experience, 1999-2009. Curr Drug Saf 2011; 6:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedapati EV, Bateman ST. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone. Pediatr Crit Care Med 2011; 12:e102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glatstein M, Finkelstein Y, Scolnik D. Accidental methadone ingestion in an infant: case report and review of the literature. Pediatr Emerg Care 2009; 25:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuehn BM. Fentanyl patch warning. JAMA 2012; 307:2139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HK, Smiddy M, Hoffman RS, Nelson LS. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics 2012; 130:e1700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shadnia S, Rahimi M, Hassanian-Moghaddam H, et al. Methadone toxicity: comparing tablet and syrup formulations during a decade in an academic poison center of Iran. Clin Toxicol (Phila) 2013; 51:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavonas EJ, Banner W, Bradt P, et al. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. J Pediatr 2013; 163:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toce MS, Burns MM, O'Donnell KA. Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center. Clin Toxicol (Phila) 2017; 55:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lovegrove MC, Mathew J, Hampp C, et al. Emergency hospitalizations for unsupervised prescription medication ingestions by young children. Pediatrics 2014; 134:e1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Post S, Spiller HA, Casavant MJ, et al. Buprenorphine Exposures Among Children and Adolescents Reported to US Poison Control Centers. Pediatrics 2018; 142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Budnitz DS, Lovegrove MC, Sapiano MR, et al. Notes from the Field: Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion - United States, 2008-2015. MMWR Morb Mortal Wkly Rep 2016; 65:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang GS, Olsen H, Severtson G, et al. The impact of the prescription opioid epidemic on young children: Trends and mortality. Drug Alcohol Depend 2020; 211:107924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaw CE, Curry AE, Osterhoudt KC, et al. Characteristics of Fatal Poisonings Among Infants and Young Children in the United States. Pediatrics 2023; 151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielssen OB, Large MM, Westmore BD, Lackersteen SM. Child homicide in New South Wales from 1991 to 2005. Med J Aust 2009; 190:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez A, Scribano PV, Perry H. An intentional opiate intoxication of an infant: when medical toxicology and child maltreatment services merge. Pediatr Emerg Care 2004; 20:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunter AA, Schwab-Reese L, DiVietro S, McCollum S. An examination of fatal child poisonings in the United States using the National Violent Death Reporting System (NVDRS), 2012-2017. Clin Toxicol (Phila) 2022; 60:342.
          </a>
         </li>
         <li class="breakAll">
          Yaksh TL, Walla MA. Opioids, Analgesic, and Pain Management. In: Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics, 12th, Brunton LL, Chabner BA, Knollman BC (Eds), McGraw-Hill, New York 2011. p.521.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhawan BN, Cesselin F, Raghubir R, et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996; 48:567.
          </a>
         </li>
         <li class="breakAll">
          Brian M. Cox, Anna Borsodi, Girolamo Caló, et al. Opioid receptors, introduction. Last modified on 10/13/2009. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/FamilyIntroductionForward?familyId=50 (Accessed on February 12, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Ther Drug Monit 1991; 13:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark RF, Wei EM, Anderson PO. Meperidine: therapeutic use and toxicity. J Emerg Med 1995; 13:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351:2827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maurer PM, Bartkowski RR. Drug interactions of clinical significance with opioid analgesics. Drug Saf 1993; 8:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz RH. Adolescent heroin use: a review. Pediatrics 1998; 102:1461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long H, Deore K, Hoffman RS, Nelson LS. A fatal case of spongiform leukoencephalopathy linked to "chasing the dragon". J Toxicol Clin Toxicol 2003; 41:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins AJ, Keenan RM, Henningfield JE, Cone EJ. Pharmacokinetics and pharmacodynamics of smoked heroin. J Anal Toxicol 1994; 18:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarabar AF, Nelson LS. The resurgence and abuse of heroin by children in the United States. Curr Opin Pediatr 2003; 15:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beno S, Calello D, Baluffi A, Henretig FM. Pediatric body packing: drug smuggling reaches a new low. Pediatr Emerg Care 2005; 21:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traub SJ, Kohn GL, Hoffman RS, Nelson LS. Pediatric "body packing". Arch Pediatr Adolesc Med 2003; 157:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas TJ, Pauze D, Love JN. Are one or two dangerous? Diphenoxylate-atropine exposure in toddlers. J Emerg Med 2008; 34:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LoVecchio F, Pizon A, Matesick L, O'Patry S. Accidental dextromethorphan ingestions in children less than 5 years old. J Med Toxicol 2008; 4:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shelly MP, Park GR. Morphine toxicity with dilated pupils. Br Med J (Clin Res Ed) 1984; 289:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordt SP. "DXM": a new drug of abuse? Ann Emerg Med 1998; 31:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sporer KA. Acute heroin overdose. Ann Intern Med 1999; 130:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sporer KA, Dorn E. Heroin-related noncardiogenic pulmonary edema : a case series. Chest 2001; 120:1628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helpern M, Rho YM. Deaths from narcotism in New York City. Incidence, circumstances, and postmortem findings. N Y State J Med 1966; 66:2391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart 2000; 83:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipski J, Stimmel B, Donoso E. The effect of heroin and multiple drug abuse on the electrocardiogram. Am Heart J 1973; 86:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005; 95:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wingert WE, Mundy LA, Nelson L, et al. Detection of clenbuterol in heroin users in twelve postmortem cases at the Philadelphia medical examiner's office. J Anal Toxicol 2008; 32:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koren G, Butt W, Pape K, Chinyanga H. Morphine-induced seizures in newborn infants. Vet Hum Toxicol 1985; 27:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control (CDC). Street-drug contaminant causing parkinsonism. MMWR Morb Mortal Wkly Rep 1984; 33:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glick C, Evans OB, Parks BR. Muscle rigidity due to fentanyl infusion in the pediatric patient. South Med J 1996; 89:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000; 85:2215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toce MS, Stefater MA, Breault DT, Burns MM. A case report of methadone-associated hypoglycemia in an 11-month-old male. Clin Toxicol (Phila) 2018; 56:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapple D, Johnson D, Connors R. Baclofen overdose in two siblings. Pediatr Emerg Care 2001; 17:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perry HE, Wright RO, Shannon MW, Woolf AD. Baclofen overdose: drug experimentation in a group of adolescents. Pediatrics 1998; 101:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baden LR, Horowitz G, Jacoby H, Eliopoulos GM. Quinolones and false-positive urine screening for opiates by immunoassay technology. JAMA 2001; 286:3115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zacher JL, Givone DM. False-positive urine opiate screening associated with fluoroquinolone use. Ann Pharmacother 2004; 38:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaffee WB, Trucco E, Levy S, Weiss RD. Is this urine really negative? A systematic review of tampering methods in urine drug screening and testing. J Subst Abuse Treat 2007; 33:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy S, Sherritt L, Vaughan BL, et al. Results of random drug testing in an adolescent substance abuse program. Pediatrics 2007; 119:e843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy S, Knight JR, Moore T, et al. Acceptability of drug testing in an outpatient substance abuse program for adolescents. J Adolesc Health 2011; 48:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osterwalder JJ. Naloxone--for intoxications with intravenous heroin and heroin mixtures--harmless or hazardous? A prospective clinical study. J Toxicol Clin Toxicol 1996; 34:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamberlain JM, Klein BL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 1994; 12:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Academy of Pediatrics Committee on Drugs: Naloxone dosage and route of administration for infants and children: addendum to emergency drug doses for infants and children. Pediatrics 1990; 86:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Purssell R, Godwin J, Moe J, et al. Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study. Clin Toxicol (Phila) 2021; 59:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berlot G, Gullo A, Romano E, Rinaldi A. Naloxone in cardiorespiratory arrest. Anaesthesia 1985; 40:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertini G, Russo L, Cricelli F, et al. Role of a prehospital medical system in reducing heroin-related deaths. Crit Care Med 1992; 20:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerr D, Kelly AM, Dietze P, et al. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction 2009; 104:2067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis JM, Klein-Schwartz W, Benson BE, et al. Continuous naloxone infusion in pediatric narcotic overdose. Am J Dis Child 1984; 138:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leblanc A, Benbrick N, Moreau MH. [Methadone poisoning in a 1-year-old child treated by continuous infusion of naloxone]. Arch Pediatr 2002; 9:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 1986; 15:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaddis GM, Watson WA. Naloxone-associated patient violence: an overlooked toxicity? Ann Pharmacother 1992; 26:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuss FM, Colaço CB, Baron JH. Cardiac arrest after reversal of effects of opiates with naloxone. Br Med J (Clin Res Ed) 1984; 288:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz JA, Koenigsberg MD. Naloxone-induced pulmonary edema. Ann Emerg Med 1987; 16:1294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan JL, Marx JA, Calabro JJ, et al. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose. Ann Emerg Med 1999; 34:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chumpa A, Kaplan RL, Burns MM, Shannon MW. Nalmefene for elective reversal of procedural sedation in children. Am J Emerg Med 2001; 19:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loiselle JM, Baker MD, Templeton JM Jr, et al. Substance abuse in adolescent trauma. Ann Emerg Med 1993; 22:1530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy-Hendricks A, Gielen A, McDonald E, et al. Medication Sharing, Storage, and Disposal Practices for Opioid Medications Among US Adults. JAMA Intern Med 2016; 176:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald EM, Kennedy-Hendricks A, McGinty EE, et al. Safe Storage of Opioid Pain Relievers Among Adults Living in Households With Children. Pediatrics 2017; 139.
          </a>
         </li>
         <li class="breakAll">
          Opioid painkiller prescribing: where you live makes a difference. CDC Vitalsigns. Centers for Disease Control and Prevention. https://www.cdc.gov/vitalsigns/opioid-prescribing/ (Accessed on April 18, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung CP, Callahan ST, Cooper WO, et al. Outpatient Opioid Prescriptions for Children and Opioid-Related Adverse Events. Pediatrics 2018; 142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCabe SE, West BT, Veliz P, et al. Trends in Medical and Nonmedical Use of Prescription Opioids Among US Adolescents: 1976-2015. Pediatrics 2017.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6504 Version 47.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1867667" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : An outbreak of designer drug--related deaths in Pennsylvania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1867667" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : An outbreak of designer drug--related deaths in Pennsylvania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7185002" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : China white: the bogus drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3874373" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/298352" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6823561" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6823561" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6823561" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6823561" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21083382" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A flood of opioids, a rising tide of deaths.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29049278" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas - United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30646334" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : US National Trends in Pediatric Deaths From Prescription and Illicit Opioids, 1999-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37155161" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : National Trends in Pediatric Deaths From Fentanyl, 1999-2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27802492" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : National Trends in Hospitalizations for Opioid Poisonings Among Children and Adolescents, 1997 to 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22566521" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Medical and nonmedical use of prescription opioids among high school seniors in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25347221" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Presentation of prescription and nonprescription opioid overdoses to US emergency departments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28320869" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Prescription Opioid Exposures Among Children and Adolescents in the United States: 2000-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21392250" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18381506" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Toxicity of buprenorphine overdoses in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15961014" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Are one or two dangerous? Opioid exposure in toddlers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17015570" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Adverse effects in children after unintentional buprenorphine exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21047302" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Accidental and non-accidental ingestion of methadone and buprenorphine in childhood: a single center experience, 1999-2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20921918" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19225381" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Accidental methadone ingestion in an infant: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Fentanyl patch warning
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23129079" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23972442" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Methadone toxicity: comparing tablet and syrup formulations during a decade in an academic poison center of Iran.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23993129" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27756148" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25225137" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Emergency hospitalizations for unsupervised prescription medication ingestions by young children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29941678" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Buprenorphine Exposures Among Children and Adolescents Reported to US Poison Control Centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27764078" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Notes from the Field: Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion - United States, 2008-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32178937" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The impact of the prescription opioid epidemic on young children: Trends and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36897244" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Characteristics of Fatal Poisonings Among Infants and Young Children in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19120000" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Child homicide in New South Wales from 1991 to 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15502660" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : An intentional opiate intoxication of an infant: when medical toxicology and child maltreatment services merge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34545746" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : An examination of fatal child poisonings in the United States using the National Violent Death Reporting System (NVDRS), 2012-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34545746" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : An examination of fatal child poisonings in the United States using the National Violent Death Reporting System (NVDRS), 2012-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8981566" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : International Union of Pharmacology. XII. Classification of opioid receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8981566" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : International Union of Pharmacology. XII. Classification of opioid receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2057987" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical pharmacokinetics of morphine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8747629" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Meperidine: therapeutic use and toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15625333" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Codeine intoxication associated with ultrarapid CYP2D6 metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8471186" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Drug interactions of clinical significance with opioid analgesics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15784664" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The serotonin syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9832585" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Adolescent heroin use: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14677803" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A fatal case of spongiform leukoencephalopathy linked to "chasing the dragon".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7823539" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Pharmacokinetics and pharmacodynamics of smoked heroin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12640281" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The resurgence and abuse of heroin by children in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16280948" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Pediatric body packing: drug smuggling reaches a new low.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12580688" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Pediatric "body packing".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17976801" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Are one or two dangerous? Diphenoxylate-atropine exposure in toddlers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19031376" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Accidental dextromethorphan ingestions in children less than 5 years old.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6435774" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Morphine toxicity with dilated pupils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9624331" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : "DXM": a new drug of abuse?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10189329" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Acute heroin overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11713145" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Heroin-related noncardiogenic pulmonary edema : a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5222195" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Deaths from narcotism in New York City. Incidence, circumstances, and postmortem findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10814617" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Recreational drug misuse: issues for the cardiologist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4743335" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The effect of heroin and multiple drug abuse on the electrocardiogram.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15781034" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Impact of methadone treatment on cardiac repolarization and conduction in opioid users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18713522" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Detection of clenbuterol in heroin users in twelve postmortem cases at the Philadelphia medical examiner's office.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4082466" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Morphine-induced seizures in newborn infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6427583" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Street-drug contaminant causing parkinsonism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8903304" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Muscle rigidity due to fentanyl infusion in the pediatric patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10852454" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Endocrine consequences of long-term intrathecal administration of opioids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28650702" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A case report of methadone-associated hypoglycemia in an 11-month-old male.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11334090" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Baclofen overdose in two siblings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9606233" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Baclofen overdose: drug experimentation in a group of adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11754677" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Quinolones and false-positive urine screening for opiates by immunoassay technology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15252190" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : False-positive urine opiate screening associated with fluoroquinolone use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17588487" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Is this urine really negative? A systematic review of tampering methods in urine drug screening and testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17403828" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Results of random drug testing in an adolescent substance abuse program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21338892" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Acceptability of drug testing in an outpatient substance abuse program for adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8699555" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Naloxone--for intoxications with intravenous heroin and heroin mixtures--harmless or hazardous? A prospective clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7945608" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A comprehensive review of naloxone for the emergency physician.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2388800" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : American Academy of Pediatrics Committee on Drugs: Naloxone dosage and route of administration for infants and children: addendum to emergency drug doses for infants and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32401548" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4037279" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Naloxone in cardiorespiratory arrest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1559363" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Role of a prehospital medical system in reducing heroin-related deaths.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19922572" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6475855" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Continuous naloxone infusion in pediatric narcotic overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12162157" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : [Methadone poisoning in a 1-year-old child treated by continuous infusion of naloxone].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3963538" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : A dosing nomogram for continuous infusion intravenous naloxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1554930" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Naloxone-associated patient violence: an overlooked toxicity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6419929" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Cardiac arrest after reversal of effects of opiates with naloxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3662194" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Naloxone-induced pulmonary edema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10381993" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11698998" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Nalmefene for elective reversal of procedural sedation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2836152" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8214830" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Substance abuse in adolescent trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27295629" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Medication Sharing, Storage, and Disposal Practices for Opioid Medications Among US Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28219969" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Safe Storage of Opioid Pain Relievers Among Adults Living in Households With Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28219969" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Safe Storage of Opioid Pain Relievers Among Adults Living in Households With Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30012559" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Outpatient Opioid Prescriptions for Children and Opioid-Related Adverse Events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28320868" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Trends in Medical and Nonmedical Use of Prescription Opioids Among US Adolescents: 1976-2015.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
